MX2012013642A - Composiciones farmaceuticas topicas que comprenden furoato de mometasona. - Google Patents

Composiciones farmaceuticas topicas que comprenden furoato de mometasona.

Info

Publication number
MX2012013642A
MX2012013642A MX2012013642A MX2012013642A MX2012013642A MX 2012013642 A MX2012013642 A MX 2012013642A MX 2012013642 A MX2012013642 A MX 2012013642A MX 2012013642 A MX2012013642 A MX 2012013642A MX 2012013642 A MX2012013642 A MX 2012013642A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
mometasone furoate
topical pharmaceutical
skin
compositions
Prior art date
Application number
MX2012013642A
Other languages
English (en)
Inventor
Fritjof Evers
Henning Mallwitz
Ricarda Meyer
Christoph Willers
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of MX2012013642A publication Critical patent/MX2012013642A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen composiciones farmacéuticas tópicas que comprenden, en base al peso total de la composición: a) 0.01 a 0.2% en peso de furoato de mometasona, b) 5 a 18% en peso de hexilenglicol, c) 20 a 40% en peso de agua, y d) 25 a 70% en peso de una fase oleosa; dichas composiciones son estables y se pueden aplicar de modo sencillo y seguro a grandes superficies de piel de modo aceptable por los pacientes en general, para el tratamiento o la prevención de psoriasis, dermatitis atópica (eczema atópico) y otros trastornos o enfermedades de la piel.
MX2012013642A 2010-05-26 2011-05-13 Composiciones farmaceuticas topicas que comprenden furoato de mometasona. MX2012013642A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10382146A EP2394653A1 (en) 2010-05-26 2010-05-26 Topical pharmaceutical compositions comprising mometasone furoate
US36505010P 2010-07-16 2010-07-16
PCT/EP2011/002369 WO2011147536A2 (en) 2010-05-26 2011-05-13 Topical pharmaceutical compositions

Publications (1)

Publication Number Publication Date
MX2012013642A true MX2012013642A (es) 2013-05-06

Family

ID=42797321

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012013642A MX2012013642A (es) 2010-05-26 2011-05-13 Composiciones farmaceuticas topicas que comprenden furoato de mometasona.

Country Status (33)

Country Link
US (2) US20140200203A1 (es)
EP (2) EP2394653A1 (es)
JP (1) JP5743241B2 (es)
KR (1) KR101790371B1 (es)
CN (1) CN102883725B (es)
AR (1) AR081765A1 (es)
AU (1) AU2011257586B2 (es)
BR (1) BR112012030006A2 (es)
CA (1) CA2794553C (es)
CL (1) CL2012003282A1 (es)
CO (1) CO6640244A2 (es)
DK (1) DK2575822T3 (es)
EA (1) EA022967B1 (es)
ES (1) ES2595250T3 (es)
HR (1) HRP20161288T1 (es)
HU (1) HUE029818T2 (es)
IL (1) IL222163B (es)
LT (1) LT2575822T (es)
ME (1) ME02555B (es)
MX (1) MX2012013642A (es)
MY (1) MY160377A (es)
NZ (1) NZ602730A (es)
PH (1) PH12012502173A1 (es)
PL (1) PL2575822T3 (es)
PT (1) PT2575822T (es)
RS (1) RS55233B1 (es)
SG (2) SG184405A1 (es)
SI (1) SI2575822T1 (es)
SM (1) SMT201600342B (es)
TW (1) TWI473615B (es)
UY (1) UY33404A (es)
WO (1) WO2011147536A2 (es)
ZA (1) ZA201208420B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2394653A1 (en) 2010-05-26 2011-12-14 Almirall, S.A. Topical pharmaceutical compositions comprising mometasone furoate
US11135297B2 (en) * 2013-07-11 2021-10-05 Pola Pharma Inc. External-use composition producing foamed state upon use
GB2540764A (en) * 2015-07-24 2017-02-01 Fontus Health Ltd Topical composition
CN110770224B (zh) * 2017-03-10 2022-11-18 罗格斯新泽西州立大学 作为外排泵抑制剂的吲哚衍生物
EP3492068A1 (en) * 2017-12-01 2019-06-05 NCP NewCare Products GmbH Composition for treating onychomycosis
US12453788B2 (en) * 2020-04-21 2025-10-28 Deloren E. Anderson Silver titanium dioxide coating material, atomized silver titanium dioxide solution for inhaling and photocatalytic titanium dioxide solution for tattoo removal
CN114767630A (zh) * 2022-06-06 2022-07-22 黑龙江中医药大学 一种治疗变应性鼻炎的药物组合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808610A (en) 1986-10-02 1989-02-28 Schering Corporation Mometasone furoate anti-inflammatory cream composition using hexylene glycol
US4775529A (en) 1987-05-21 1988-10-04 Schering Corporation Steroid lotion
WO1991008733A1 (en) 1989-12-20 1991-06-27 Schering Corporation Stable cream and lotion bases for lipophilic drug compositions
WO1995017196A1 (en) 1993-12-21 1995-06-29 Schering Corporation Psoriasis treatment
US5696105A (en) * 1996-03-14 1997-12-09 Hackler; Walter A. Antifungal nail composition
EP1033991B1 (en) 1997-10-09 2002-04-17 Schering Corporation Mometasone furoate suspensions for nebulization
TR200201343A2 (tr) 2002-05-17 2003-12-22 Orva İlaç Sanayi̇ Ve Ti̇caret A. Ş. Kortikosteroid ve antiseptik içeren farmasötik bileşim
US7312207B2 (en) 2003-05-23 2007-12-25 Taro Pharmaceuticals North America, Inc. Topical steroid cream formulations
DE102006034883A1 (de) 2006-07-25 2008-01-31 Hermal Kurt Herrmann Gmbh & Co. Ohg Pharmazeutische Zusammensetzung enthaltend Mometasonfuroat
EP2120868A4 (en) 2007-04-11 2010-08-25 Perrigo Israel Phamaceuticals LOW-DOSED MOMETASON FORMULATIONS
EP2394653A1 (en) 2010-05-26 2011-12-14 Almirall, S.A. Topical pharmaceutical compositions comprising mometasone furoate

Also Published As

Publication number Publication date
CA2794553A1 (en) 2011-12-01
MY160377A (en) 2017-03-15
PH12012502173A1 (en) 2013-02-04
EP2394653A1 (en) 2011-12-14
AU2011257586B2 (en) 2014-04-17
EP2575822A2 (en) 2013-04-10
DK2575822T3 (en) 2016-10-17
CN102883725A (zh) 2013-01-16
ZA201208420B (en) 2013-09-25
HRP20161288T1 (hr) 2016-11-18
JP5743241B2 (ja) 2015-07-01
IL222163B (en) 2018-01-31
WO2011147536A3 (en) 2012-06-07
ME02555B (me) 2017-02-20
HUE029818T2 (en) 2017-04-28
SG10201502252YA (en) 2015-05-28
JP2013530149A (ja) 2013-07-25
CN102883725B (zh) 2015-04-01
AR081765A1 (es) 2012-10-17
US20160038512A1 (en) 2016-02-11
NZ602730A (en) 2014-03-28
EA022967B1 (ru) 2016-03-31
SI2575822T1 (sl) 2016-11-30
ES2595250T3 (es) 2016-12-28
CL2012003282A1 (es) 2013-01-25
HK1177893A1 (zh) 2013-08-30
CO6640244A2 (es) 2013-03-22
US9907807B2 (en) 2018-03-06
EP2575822B1 (en) 2016-07-06
KR20130086137A (ko) 2013-07-31
WO2011147536A2 (en) 2011-12-01
PL2575822T3 (pl) 2017-01-31
UY33404A (es) 2011-12-01
EA201291335A1 (ru) 2013-04-30
SG184405A1 (en) 2012-11-29
TWI473615B (zh) 2015-02-21
CA2794553C (en) 2018-01-02
US20140200203A1 (en) 2014-07-17
TW201204367A (en) 2012-02-01
AU2011257586A1 (en) 2012-11-01
SMT201600342B (it) 2017-01-10
RS55233B1 (sr) 2017-02-28
LT2575822T (lt) 2016-10-10
KR101790371B1 (ko) 2017-10-25
BR112012030006A2 (pt) 2016-08-02
PT2575822T (pt) 2016-10-06

Similar Documents

Publication Publication Date Title
PH12012502173A1 (en) Topical pharmaceutical compositions comprising mometasone furoate
WO2014188276A3 (en) Antioxidant compositions and methods of using the same
MX377629B (es) Composiciones farmacéuticas tópicas.
WO2011156030A3 (en) High oil-content emollient aerosol foam compositions
WO2012085523A3 (en) Skin sanitizer compositions comprising alcohol based emulsion
HK1216506A1 (zh) 含硒組合物及其治療和預防與線粒體功能障礙有關的疾病或病症的應用
MX2013004329A (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
HK1212251A1 (en) Topical compositions and methods of use
WO2011117377A3 (en) Compositions comprising brimonidine for the treatment of erythema
SA113340494B1 (ar) تركيبة لعلاج اضطرابات أيضية
MX2015003074A (es) Formulaciones que comprenden idebenona, n-acetil-s-farnesil-l-cist eína y ergotioneína y usos de las mismas.
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
WO2011149301A3 (en) A composition comprising the extract of physalis alkekengi var. francheti hort as an active ingredient for preventing and treating inflammatory diseases
WO2014178789A9 (en) Topical composition and carrier for administration of pharmaceutically or cosmetically active ingredients
WO2013190542A3 (en) Topical compositions for the treatment of chronic inflammatory skin disease
MX342859B (es) Polisacarido de las semillas de tamarindo para usarse en el tratamiento de enfermedades inflamatorias.
MX353580B (es) Acido graso monoinsaturado para prevenir y/o tratar las imperfecciones del color de la piel.
MX2013002119A (es) Sustituidas-2-oxo- y 2-tioxo-dihidroquinolin-3-carboxamidas como moduladores de kcnq2/3.
MX2016008546A (es) Reduccion de queloides utilizando alantoina topica.
MY170724A (en) Use of certain trioxygenated benzene derivatives in body fat management
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
GB201312583D0 (en) Combination and composition for treating obesity
WO2012044963A3 (en) Perfluorocarbons for use in treating pruritus
HK1210173A1 (en) Substituted 6-amino-nicotinamides bearing an oh-containing group as kcnq2/3 modulators
WO2012172218A3 (fr) Complexe d'extraits végétaux pour la protection de la peau.

Legal Events

Date Code Title Description
FG Grant or registration